
C4X receives $11m milestone payment from AstraZeneca
Betsy Goodfellow | January 3, 2024 | News story | Sales and Marketing |ย ย AstraZeneca, C4X, C4X Discovery, Chronic Diseasesย
C4X Discovery Holdings has announced that it has received a milestone payment of $11m from AstraZeneca which has been triggered by the preclinical progress of C4XDโs NRF2 Activator programme.
The license agreement was announced in November 2022, under which C4XD received an initial payment of $2m as well as potentially being entitled to a further $400m in preclinical, clinical development and commercial milestones, alongside tiered mid-single digit royalties on future sales.
Currently, AstraZeneca is working on the development of C4XDโs former NRF2 Activator programme intended to deliver an oral therapy for the treatment of inflammatory and respiratory diseases, although the lead focus is chronic respiratory disease.
Clive Dix, chief executive officer of C4X Discovery, commented: โThis significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator programme forward. NRF2 is a challenging target and this achievement provides further validation of our ability to generate differentiated, quality molecules in immuno-inflammation. We believe that our unique approach can deliver transformative oral therapies for patients suffering from immuno-inflammatory diseases. This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024.โ
Betsy Goodfellow
Related Content

NICE recommends Benralizumab for Rare Form of Vasculitis
The National Institute for Health and Care Excellence (NICE) has recommended AstraZenecaโs benralizumab (Fasenra) as …

NICE approves AstraZenecaโs dual immunotherapy for advanced liver cancer
AstraZeneca has received a positive recommendation from the National Institute for Health and Care Excellence …

Purpose and people: the enduring power of brand and the evolution of employer identity
Two decades ago, terms like purpose and people were rarely at the forefront of branding …






